ArticleJournal of fungi (Basel, Switzerland)2021
Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from
Article in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Antifungal Susceptibility Patterns in Respiratory Tract Candidiasis and Risk Factors Among HIV-Infected Adults in South West Cameroon.Antibiotics (Basel, Switzerland) · 2026Article
- Secretion of serine proteases by planktonic- and biofilm-growing cells of Candida parapsilosis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Structural and Functional Insights into Viral and Fungal Proteins Involved in Chronic Inflammation and Their Biologic Treatments.Pharmaceutics · 2025Review
- Biofilm production by the multidrug-resistant fungusAIMS microbiology · 2025Article
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- MIG1, TUP1 and NRG1 mediated yeast to hyphal morphogenesis inhibition in Candida albicans by ganciclovir.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Saps1-3 Antigens inInfectious disease reports · 2024Article
- Secreted Aspartic Proteinases: Key Factors inInternational journal of molecular sciences · 2024Review
- Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses.Infection and drug resistance · 2024Review
- Silver(I) 1,10-Phenanthroline Complexes Are Active againstJournal of fungi (Basel, Switzerland) · 2023Article
- Mycological evaluation of frozen meat with special reference to yeasts.Veterinary world · 2023Article
- Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments againstCurrent issues in molecular biology · 2022Article
- Lopinavir-menthol co-crystals for enhanced dissolution rate and intestinal absorption.Journal of drug delivery science and technology · 2022Article
- Special Issue: Alternative Therapeutic Approaches ofJournal of fungi (Basel, Switzerland) · 2022Article
- From Naturally-Sourced Protease Inhibitors to New Treatments for Fungal Infections.Journal of fungi (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
The repurposing strategy was applied herein to evaluate the effects of lopinavir, an aspartic protease inhibitor currently used in the treatment of HIV-infected individuals, on the globally widespread opportunistic human fungal pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.